13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. 1993

S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D015474 Isotretinoin A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects. 13-cis-Retinoic Acid,Accutane,Isotretinoin Zinc Salt, 13-cis-Isomer,Ro 4-3780,Roaccutane,13 cis Retinoic Acid,Isotretinoin Zinc Salt, 13 cis Isomer,Ro 4 3780,Ro 43780

Related Publications

S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
April 2002, American journal of clinical oncology,
S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
January 1998, European journal of gynaecological oncology,
S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
March 1995, Gynecologic oncology,
S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
October 1998, The journal of obstetrics and gynaecology research,
S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
February 1992, Journal of the National Cancer Institute,
S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
June 1994, Journal of the National Cancer Institute,
S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
January 1994, Cancer chemotherapy and pharmacology,
S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
May 1994, Annals of oncology : official journal of the European Society for Medical Oncology,
S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
January 1997, European journal of cancer (Oxford, England : 1990),
S M Lippman, and J J Kavanagh, and M Paredes-Espinoza, and F Delgadillo-Madrueño, and P Paredes-Casillas, and W K Hong, and G Massimini, and E E Holdener, and I H Krakoff
February 1993, Anti-cancer drugs,
Copied contents to your clipboard!